LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, raised $101 million by offering 6.7 million shares at $15, within the range of $14 to $16.
The company is focused on developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Its lead candidate, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and acute myeloid leukemia (AML). In November 2020, the company filed a CTA to conduct a Phase 1/2a trial with LAVA-051 in relapsed and/or refractory CLL, MM and AML, which it expects to begin enrolling in the 1H21.
LAVA Therapeutics plans to list on the Nasdaq under the symbol LVTX. J.P. Morgan, Jefferies and SVB Leerink acted as lead managers on the deal.
